Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 1, Pages 76-85
Publisher
Springer Nature
Online
2014-05-12
DOI
10.1038/leu.2014.156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
- (2015) Wolfgang Warsch et al. Oncotarget
- Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition
- (2013) Pavel Simara et al. AMERICAN JOURNAL OF HEMATOLOGY
- Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis
- (2013) T. O'Hare et al. CANCER RESEARCH
- Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
- (2013) L. Casetti et al. CANCER RESEARCH
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- Low GFI1 expression in white blood cells of CP–CML patients at diagnosis is strongly associated with subsequent blastic transformation
- (2013) C H Kok et al. LEUKEMIA
- Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells
- (2012) M-C Wagner et al. LEUKEMIA
- Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1
- (2012) A R Soliera et al. LEUKEMIA
- BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
- (2012) Oliver Hantschel et al. Nature Chemical Biology
- Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells
- (2012) Daniel B. Lipka et al. PLoS One
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1
- (2011) Osamu Yamada et al. CELLULAR SIGNALLING
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
- (2011) E Traer et al. LEUKEMIA
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia
- (2010) Andrea Hoelbl et al. EMBO Molecular Medicine
- Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors
- (2010) D K Hiwase et al. LEUKEMIA
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
- (2010) A Samanta et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis
- (2009) J. L. Snead et al. BLOOD
- Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
- (2009) H. Kantarjian et al. BLOOD
- Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells
- (2009) D K Hiwase et al. LEUKEMIA
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
- (2008) Neil P. Shah et al. CANCER CELL
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- Metabolism and Disposition of Dasatinib after Oral Administration to Humans
- (2008) L. J. Christopher et al. DRUG METABOLISM AND DISPOSITION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search